Eam Investors, LLC Cardiff Oncology, Inc. Transaction History

Eam Investors, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$1.46 - $5.91 $236,378 - $956,846	161,903 New	161,903 $864,000
Q1 2021 May 11, 2021	SELL	$9.1 - $19.57 $414,204 - $890,767	-45,517 Closed	0 $0
Q4 2020 Feb 11, 2021	SELL	$12.02 - $24.71 $3.45 Million - $7.1 Million	-287,383 Reduced 86.33%	45,517 $819,000
Q3 2020 Nov 13, 2020	BUY	$4.25 - $14.19 $869,082 - $2.9 Million	204,490 Added 159.25%	332,900 $4.72 Million
Q2 2020 Aug 13, 2020	BUY	$0.78 - $5.1 $100,159 - $654,891	128,410 New	128,410 $643,000

126

21.9M

1.11M

150K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $93.2M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.